Galectin Therapeutics Inc. (GALT) 10-Year Financial Performance & Capital Metrics

GALT • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

AboutGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Show more

Revenue $0
EBITDA -$42M -11.5%
Net Income -$47M -14.6%
EPS (Diluted) -0.76 -2.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -7.66 +43.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM17.25%

EPS CAGR

10Y-

5Y-

3Y-

TTM19.18%

ROCE

10Y Avg-172.33%

5Y Avg-181.48%

3Y Avg-276.45%

Latest-

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	7K	7K	1K	0	35K	36K	41K	32K	33K	37K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-7K	-7K	-1K	0	-35K	-36K	-41K	-32K	-33K	-37K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	0%	0.86%	1%	-	-0.03%	-0.14%	0.22%	-0.03%	-0.12%
Operating Expenses+	20.08M	21.48M	16.25M	13.6M	13.4M	23.41M	30.14M	38.32M	38.04M	42.4M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	6.96M	6.16M	4.53M	7.13M	5.94M	5.43M	6.32M	6.58M	5.94M	5.83M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	13.11M	15.32M	11.72M	6.47M	7.47M	17.98M	23.82M	31.74M	32.13M	36.57M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-20.08M	-21.48M	-16.25M	-13.6M	-13.44M	-23.44M	-30.18M	-38.35M	-38.07M	-42.43M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.3%	-0.07%	0.24%	0.16%	0.01%	-0.74%	-0.29%	-0.27%	0.01%	-0.11%
EBITDA+	-20.07M	-21.47M	-16.25M	-13.6M	-13.4M	-23.41M	-30.14M	-38.32M	-38.04M	-42.4M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.3%	-0.07%	0.24%	0.16%	0.01%	-0.75%	-0.29%	-0.27%	0.01%	-0.11%
D&A (Non-Cash Add-back)	7K	7K	1K	1K	35K	36K	41K	32K	33K	37K
EBIT	-20.03M	-21.48M	-16.23M	-13.56M	-13.21M	-23.38M	-30.04M	-37.74M	-38.27M	-41.51M
Net Interest Income+	0	0	12K	-298K	144K	-21K	-486K	-981K	-2.56M	-5.2M
Interest Income	52K	45K	24K	38K	231K	66K	3K	52K	230K	338K
Interest Expense	0	0	12K	336K	87K	87K	489K	1.03M	2.79M	5.54M
Other Income/Expense	52K	45K	12K	-298K	144K	-21K	-348K	-424K	-2.99M	-4.61M
Pretax Income+	-20.03M	-21.44M	-16.23M	-13.9M	-13.29M	-23.46M	-30.53M	-38.78M	-41.07M	-47.05M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-20.03M	-21.44M	-16.23M	-13.9M	-13.29M	-23.46M	-30.53M	-38.78M	-41.07M	-47.05M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.27%	-0.07%	0.24%	0.14%	0.04%	-0.77%	-0.3%	-0.27%	-0.06%	-0.15%
Net Income (Continuing)	-20.03M	-21.44M	-16.23M	-13.9M	-13.29M	-23.46M	-30.53M	-38.78M	-41.07M	-47.05M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.83	-0.73	-0.46	-0.35	-0.39	-0.41	-0.52	-0.65	-0.74	-0.76
EPS Growth %	-0.15%	0.12%	0.37%	0.24%	-0.11%	-0.05%	-0.27%	-0.25%	-0.14%	-0.03%
EPS (Basic)	-0.83	-0.73	-0.46	-0.35	-0.39	-0.41	-0.52	-0.65	-0.74	-0.76
Diluted Shares Outstanding	24.12M	29.22M	35.52M	39.41M	52.24M	57.03M	58.53M	59.39M	60.16M	62.31M
Basic Shares Outstanding	24.12M	29.22M	35.52M	39.41M	52.24M	57.03M	58.53M	59.39M	60.16M	62.31M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	26.4M	15.79M	3.82M	8.83M	48.21M	29.46M	41.82M	20.55M	27.71M	17.25M
Cash & Short-Term Investments	25.85M	15.36M	3.05M	8.25M	47.48M	27.14M	39.65M	18.59M	25.66M	15.12M
Cash Only	25.85M	15.36M	3.05M	8.25M	47.48M	27.14M	39.65M	18.59M	25.66M	15.12M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	6K	6K	6K	579K	729K	2.32M	2.17M	1.96M	2.05M	2.13M
Total Non-Current Assets+	8K	1K	342K	174K	258K	135K	7K	733K	490K	243K
Property, Plant & Equipment	0	0	0	0	0	0	0	0	53K	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	8K	1K	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	342K	174K	258K	135K	7K	733K	437K	243K
Total Assets+	26.41M	15.79M	4.16M	9.01M	48.47M	29.6M	41.83M	21.29M	28.2M	17.5M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.11%	-0.4%	-0.74%	1.16%	4.38%	-0.39%	0.41%	-0.49%	0.32%	-0.38%
Total Current Liabilities+	1.36M	3.78M	2.97M	2.11M	2.82M	5.4M	9.03M	13.01M	15.68M	35.41M
Accounts Payable	448K	910K	608K	297K	1.66M	1.29M	1.8M	3.89M	6.43M	5.66M
Days Payables Outstanding	23.36K	47.45K	221.92K	-	17.32K	13.1K	16.07K	44.37K	71.13K	55.8K
Short-Term Debt	0	0	0	0	0	0	0	0	0	21.12M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	286K	2.19M	1.57M	517K	147K	3.27M	6.49M	8.11M	8.07M	1.89M
Current Ratio	19.41x	4.18x	1.29x	4.19x	17.10x	5.46x	4.63x	1.58x	1.77x	0.49x
Quick Ratio	19.41x	4.18x	1.29x	4.19x	17.10x	5.46x	4.63x	1.58x	1.77x	0.49x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	52K	8K	30.18M	40.47M	72.77M	85.16M
Long-Term Debt	0	0	0	0	0	0	29.05M	39.83M	71.74M	85.11M
Capital Lease Obligations	0	0	0	0	0	0	0	0	20K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	52K	8K	1.13M	639K	1M	47K
Total Liabilities	1.36M	3.78M	2.97M	2.11M	2.87M	5.41M	39.21M	53.48M	88.44M	120.56M
Total Debt+	0	0	0	0	39K	44K	29.06M	39.87M	71.81M	106.25M
Net Debt	-25.85M	-15.36M	-3.05M	-8.25M	-47.44M	-27.1M	-10.59M	21.28M	46.15M	91.13M
Debt / Equity	-	-	-	-	0.00x	0.00x	11.11x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-1353.92x	-40.48x	-154.46x	-269.47x	-61.72x	-37.13x	-13.64x	-7.66x
Total Equity+	25.05M	12.02M	1.19M	6.9M	45.59M	24.19M	2.62M	-32.19M	-60.24M	-103.07M
Equity Growth %	-0.1%	-0.52%	-0.9%	4.78%	5.61%	-0.47%	-0.89%	-13.31%	-0.87%	-0.71%
Book Value per Share	1.04	0.41	0.03	0.18	0.87	0.42	0.04	-0.54	-1.00	-1.65
Total Shareholders' Equity	25.05M	12.02M	1.19M	6.9M	45.59M	24.19M	2.62M	-32.19M	-60.24M	-103.07M
Common Stock	28K	33K	36K	41K	56K	56K	59K	59K	61K	62K
Retained Earnings	-140.05M	-163.7M	-181.17M	-196.22M	-216.39M	-240M	-270.69M	-309.57M	-354.37M	-401.57M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-16.98M	-16.41M	-15.89M	-10.18M	-10.85M	-20.6M	-24.31M	-31.06M	-32.97M	-41.77M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.37%	0.03%	0.03%	0.36%	-0.07%	-0.9%	-0.18%	-0.28%	-0.06%	-0.27%
Net Income	-20.03M	-21.44M	-16.23M	-13.9M	-13.29M	-23.46M	-30.53M	-38.78M	-41.07M	-47.05M
Depreciation & Amortization	7K	7K	1K	0	35K	36K	41K	32K	33K	37K
Stock-Based Compensation	3.4M	2.48M	1.1M	4.45M	1.68M	1.8M	2.08M	2.87M	2.26M	2.45M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	0	0	45K	348K	87K	87K	351K	-147K	1.13M	512K
Working Capital Changes	-363K	2.54M	-804K	-1.07M	641K	942K	3.75M	4.97M	4.68M	2.28M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-342K	2.42M	-812K	-1.09M	997K	2.54M	3.69M	4.24M	2.67M	-2.07M
Cash from Investing+	0	0	0	0	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-400K	0	0	0	0	0	0	0	0	0
Cash from Financing+	13.7M	5.92M	3.58M	15.38M	50.08M	263K	36.81M	10M	40.03M	31.23M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-943K	-741K	-1.23M	-915K	-394K	-137K	-171K	0	0	-91K
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	943K	741K	1.23M	915K	0	137K	171K	0	10.03M	91K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-16.98M	-16.41M	-15.89M	-10.18M	-10.85M	-20.6M	-24.31M	-31.06M	-32.97M	-41.77M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.37%	0.03%	0.03%	0.36%	-0.07%	-0.9%	-0.18%	-0.28%	-0.06%	-0.27%
FCF per Share	-0.70	-0.56	-0.45	-0.26	-0.21	-0.36	-0.42	-0.52	-0.55	-0.67
FCF Conversion (FCF/Net Income)	0.85x	0.77x	0.98x	0.73x	0.82x	0.88x	0.80x	0.80x	0.80x	0.89x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-75.54%	-115.67%	-245.84%	-343.59%	-50.65%	-67.25%	-227.74%	-	-	-
Debt / Equity	-	-	-	-	0.00x	0.00x	11.11x	-	-	-
Interest Coverage	-	-	-1353.92x	-40.48x	-154.46x	-269.47x	-61.72x	-37.13x	-13.64x	-7.66x
FCF Conversion	0.85x	0.77x	0.98x	0.73x	0.82x	0.88x	0.80x	0.80x	0.80x	0.89x

Frequently Asked Questions

Growth & Financials

Galectin Therapeutics Inc. (GALT) grew revenue by 0.0% over the past year. Growth has been modest.

Galectin Therapeutics Inc. (GALT) reported a net loss of $37.3M for fiscal year 2024.

Dividend & Returns

Galectin Therapeutics Inc. (GALT) does not currently pay a meaningful dividend. The company may be reinvesting profits for growth.

Galectin Therapeutics Inc. (GALT) had negative free cash flow of $30.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Galectin Therapeutics Inc. (GALT) 10-Year Financial Performance & Capital Metrics

GALT • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

Revenue $0
EBITDA -$42M -11.5%
Net Income -$47M -14.6%
EPS (Diluted) -0.76 -2.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -7.66 +43.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM17.25%

EPS CAGR

10Y-

5Y-

3Y-

TTM19.18%

ROCE

10Y Avg-172.33%

5Y Avg-181.48%

3Y Avg-276.45%

Latest-

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	7K	7K	1K	0	35K	36K	41K	32K	33K	37K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-7K	-7K	-1K	0	-35K	-36K	-41K	-32K	-33K	-37K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	0%	0.86%	1%	-	-0.03%	-0.14%	0.22%	-0.03%	-0.12%
Operating Expenses+	20.08M	21.48M	16.25M	13.6M	13.4M	23.41M	30.14M	38.32M	38.04M	42.4M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	6.96M	6.16M	4.53M	7.13M	5.94M	5.43M	6.32M	6.58M	5.94M	5.83M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	13.11M	15.32M	11.72M	6.47M	7.47M	17.98M	23.82M	31.74M	32.13M	36.57M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-20.08M	-21.48M	-16.25M	-13.6M	-13.44M	-23.44M	-30.18M	-38.35M	-38.07M	-42.43M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.3%	-0.07%	0.24%	0.16%	0.01%	-0.74%	-0.29%	-0.27%	0.01%	-0.11%
EBITDA+	-20.07M	-21.47M	-16.25M	-13.6M	-13.4M	-23.41M	-30.14M	-38.32M	-38.04M	-42.4M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.3%	-0.07%	0.24%	0.16%	0.01%	-0.75%	-0.29%	-0.27%	0.01%	-0.11%
D&A (Non-Cash Add-back)	7K	7K	1K	1K	35K	36K	41K	32K	33K	37K
EBIT	-20.03M	-21.48M	-16.23M	-13.56M	-13.21M	-23.38M	-30.04M	-37.74M	-38.27M	-41.51M
Net Interest Income+	0	0	12K	-298K	144K	-21K	-486K	-981K	-2.56M	-5.2M
Interest Income	52K	45K	24K	38K	231K	66K	3K	52K	230K	338K
Interest Expense	0	0	12K	336K	87K	87K	489K	1.03M	2.79M	5.54M
Other Income/Expense	52K	45K	12K	-298K	144K	-21K	-348K	-424K	-2.99M	-4.61M
Pretax Income+	-20.03M	-21.44M	-16.23M	-13.9M	-13.29M	-23.46M	-30.53M	-38.78M	-41.07M	-47.05M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-20.03M	-21.44M	-16.23M	-13.9M	-13.29M	-23.46M	-30.53M	-38.78M	-41.07M	-47.05M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.27%	-0.07%	0.24%	0.14%	0.04%	-0.77%	-0.3%	-0.27%	-0.06%	-0.15%
Net Income (Continuing)	-20.03M	-21.44M	-16.23M	-13.9M	-13.29M	-23.46M	-30.53M	-38.78M	-41.07M	-47.05M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.83	-0.73	-0.46	-0.35	-0.39	-0.41	-0.52	-0.65	-0.74	-0.76
EPS Growth %	-0.15%	0.12%	0.37%	0.24%	-0.11%	-0.05%	-0.27%	-0.25%	-0.14%	-0.03%
EPS (Basic)	-0.83	-0.73	-0.46	-0.35	-0.39	-0.41	-0.52	-0.65	-0.74	-0.76
Diluted Shares Outstanding	24.12M	29.22M	35.52M	39.41M	52.24M	57.03M	58.53M	59.39M	60.16M	62.31M
Basic Shares Outstanding	24.12M	29.22M	35.52M	39.41M	52.24M	57.03M	58.53M	59.39M	60.16M	62.31M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	26.4M	15.79M	3.82M	8.83M	48.21M	29.46M	41.82M	20.55M	27.71M	17.25M
Cash & Short-Term Investments	25.85M	15.36M	3.05M	8.25M	47.48M	27.14M	39.65M	18.59M	25.66M	15.12M
Cash Only	25.85M	15.36M	3.05M	8.25M	47.48M	27.14M	39.65M	18.59M	25.66M	15.12M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	6K	6K	6K	579K	729K	2.32M	2.17M	1.96M	2.05M	2.13M
Total Non-Current Assets+	8K	1K	342K	174K	258K	135K	7K	733K	490K	243K
Property, Plant & Equipment	0	0	0	0	0	0	0	0	53K	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	8K	1K	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	342K	174K	258K	135K	7K	733K	437K	243K
Total Assets+	26.41M	15.79M	4.16M	9.01M	48.47M	29.6M	41.83M	21.29M	28.2M	17.5M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.11%	-0.4%	-0.74%	1.16%	4.38%	-0.39%	0.41%	-0.49%	0.32%	-0.38%
Total Current Liabilities+	1.36M	3.78M	2.97M	2.11M	2.82M	5.4M	9.03M	13.01M	15.68M	35.41M
Accounts Payable	448K	910K	608K	297K	1.66M	1.29M	1.8M	3.89M	6.43M	5.66M
Days Payables Outstanding	23.36K	47.45K	221.92K	-	17.32K	13.1K	16.07K	44.37K	71.13K	55.8K
Short-Term Debt	0	0	0	0	0	0	0	0	0	21.12M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	286K	2.19M	1.57M	517K	147K	3.27M	6.49M	8.11M	8.07M	1.89M
Current Ratio	19.41x	4.18x	1.29x	4.19x	17.10x	5.46x	4.63x	1.58x	1.77x	0.49x
Quick Ratio	19.41x	4.18x	1.29x	4.19x	17.10x	5.46x	4.63x	1.58x	1.77x	0.49x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	52K	8K	30.18M	40.47M	72.77M	85.16M
Long-Term Debt	0	0	0	0	0	0	29.05M	39.83M	71.74M	85.11M
Capital Lease Obligations	0	0	0	0	0	0	0	0	20K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	52K	8K	1.13M	639K	1M	47K
Total Liabilities	1.36M	3.78M	2.97M	2.11M	2.87M	5.41M	39.21M	53.48M	88.44M	120.56M
Total Debt+	0	0	0	0	39K	44K	29.06M	39.87M	71.81M	106.25M
Net Debt	-25.85M	-15.36M	-3.05M	-8.25M	-47.44M	-27.1M	-10.59M	21.28M	46.15M	91.13M
Debt / Equity	-	-	-	-	0.00x	0.00x	11.11x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-1353.92x	-40.48x	-154.46x	-269.47x	-61.72x	-37.13x	-13.64x	-7.66x
Total Equity+	25.05M	12.02M	1.19M	6.9M	45.59M	24.19M	2.62M	-32.19M	-60.24M	-103.07M
Equity Growth %	-0.1%	-0.52%	-0.9%	4.78%	5.61%	-0.47%	-0.89%	-13.31%	-0.87%	-0.71%
Book Value per Share	1.04	0.41	0.03	0.18	0.87	0.42	0.04	-0.54	-1.00	-1.65
Total Shareholders' Equity	25.05M	12.02M	1.19M	6.9M	45.59M	24.19M	2.62M	-32.19M	-60.24M	-103.07M
Common Stock	28K	33K	36K	41K	56K	56K	59K	59K	61K	62K
Retained Earnings	-140.05M	-163.7M	-181.17M	-196.22M	-216.39M	-240M	-270.69M	-309.57M	-354.37M	-401.57M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-16.98M	-16.41M	-15.89M	-10.18M	-10.85M	-20.6M	-24.31M	-31.06M	-32.97M	-41.77M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.37%	0.03%	0.03%	0.36%	-0.07%	-0.9%	-0.18%	-0.28%	-0.06%	-0.27%
Net Income	-20.03M	-21.44M	-16.23M	-13.9M	-13.29M	-23.46M	-30.53M	-38.78M	-41.07M	-47.05M
Depreciation & Amortization	7K	7K	1K	0	35K	36K	41K	32K	33K	37K
Stock-Based Compensation	3.4M	2.48M	1.1M	4.45M	1.68M	1.8M	2.08M	2.87M	2.26M	2.45M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	0	0	45K	348K	87K	87K	351K	-147K	1.13M	512K
Working Capital Changes	-363K	2.54M	-804K	-1.07M	641K	942K	3.75M	4.97M	4.68M	2.28M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-342K	2.42M	-812K	-1.09M	997K	2.54M	3.69M	4.24M	2.67M	-2.07M
Cash from Investing+	0	0	0	0	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-400K	0	0	0	0	0	0	0	0	0
Cash from Financing+	13.7M	5.92M	3.58M	15.38M	50.08M	263K	36.81M	10M	40.03M	31.23M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-943K	-741K	-1.23M	-915K	-394K	-137K	-171K	0	0	-91K
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	943K	741K	1.23M	915K	0	137K	171K	0	10.03M	91K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-16.98M	-16.41M	-15.89M	-10.18M	-10.85M	-20.6M	-24.31M	-31.06M	-32.97M	-41.77M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.37%	0.03%	0.03%	0.36%	-0.07%	-0.9%	-0.18%	-0.28%	-0.06%	-0.27%
FCF per Share	-0.70	-0.56	-0.45	-0.26	-0.21	-0.36	-0.42	-0.52	-0.55	-0.67
FCF Conversion (FCF/Net Income)	0.85x	0.77x	0.98x	0.73x	0.82x	0.88x	0.80x	0.80x	0.80x	0.89x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-75.54%	-115.67%	-245.84%	-343.59%	-50.65%	-67.25%	-227.74%	-	-	-
Debt / Equity	-	-	-	-	0.00x	0.00x	11.11x	-	-	-
Interest Coverage	-	-	-1353.92x	-40.48x	-154.46x	-269.47x	-61.72x	-37.13x	-13.64x	-7.66x
FCF Conversion	0.85x	0.77x	0.98x	0.73x	0.82x	0.88x	0.80x	0.80x	0.80x	0.89x

Frequently Asked Questions

Growth & Financials

Galectin Therapeutics Inc. (GALT) grew revenue by 0.0% over the past year. Growth has been modest.

Galectin Therapeutics Inc. (GALT) reported a net loss of $37.3M for fiscal year 2024.

Dividend & Returns

Galectin Therapeutics Inc. (GALT) does not currently pay a meaningful dividend. The company may be reinvesting profits for growth.

Galectin Therapeutics Inc. (GALT) had negative free cash flow of $30.6M in fiscal year 2024, likely due to heavy capital investments.